{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:13:12Z","timestamp":1787317992806,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015237","name":"Medicines Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015237","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017077","name":"Hospira","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014384","name":"Amarin Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014384","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ahj.2019.08.001","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T01:55:00Z","timestamp":1565315700000},"page":"72-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial"],"prefix":"10.1016","volume":"217","author":[{"given":"Kausik K.","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry D","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan O.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Kulikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ahj.2019.08.001_bb0005","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.ahj.2019.08.001_bb0010","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJMc1300057","article-title":"Dalcetrapib in patients with an acute coronary syndrome","volume":"368","author":"Schwartz","year":"2013","journal-title":"N Engl J Med."},{"issue":"22","key":"10.1016\/j.ahj.2019.08.001_bb0015","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"issue":"19","key":"10.1016\/j.ahj.2019.08.001_bb0020","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/eurheartj\/ehl220","article-title":"Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J."},{"issue":"12","key":"10.1016\/j.ahj.2019.08.001_bb0025","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.ahj.2019.08.001_bb0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00125-018-4801-1","article-title":"Cardiovascular outcome trials of glucose-lowering medications: an update","volume":"62","author":"Home","year":"2019","journal-title":"Diabetologia."},{"issue":"23","key":"10.1016\/j.ahj.2019.08.001_bb0035","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med."},{"issue":"14","key":"10.1016\/j.ahj.2019.08.001_bb0040","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med."},{"issue":"15","key":"10.1016\/j.ahj.2019.08.001_bb0045","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2014.3321","article-title":"Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial","volume":"311","author":"Lincoff","year":"2014","journal-title":"JAMA."},{"issue":"31","key":"10.1016\/j.ahj.2019.08.001_bb0050","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/eurheartj\/eht149","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I","volume":"34","author":"Paneni","year":"2013","journal-title":"Eur Heart J."},{"issue":"5","key":"10.1016\/j.ahj.2019.08.001_bb0055","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat Rev Drug Discov."},{"issue":"4","key":"10.1016\/j.ahj.2019.08.001_bb0060","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","article-title":"The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription","volume":"19","author":"Jang","year":"2005","journal-title":"Mol Cell."},{"issue":"11","key":"10.1016\/j.ahj.2019.08.001_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111849","article-title":"The bromodomain and extra-terminal domain (BET) family: functional anatomy of BET paralogous proteins","volume":"17","author":"Taniguchi","year":"2016","journal-title":"Int J Mol Sci."},{"issue":"4","key":"10.1016\/j.ahj.2019.08.001_bb0070","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","article-title":"Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4","volume":"19","author":"Yang","year":"2005","journal-title":"Mol Cell."},{"issue":"36","key":"10.1016\/j.ahj.2019.08.001_bb0075","doi-asserted-by":"crossref","first-page":"14532","DOI":"10.1073\/pnas.1212264109","article-title":"Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors","volume":"109","author":"Bandukwala","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"10.1016\/j.ahj.2019.08.001_bb0080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","article-title":"NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis","volume":"56","author":"Brown","year":"2014","journal-title":"Mol Cell."},{"issue":"55","key":"10.1016\/j.ahj.2019.08.001_bb0085","first-page":"489","article-title":"Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation","volume":"10","author":"Denis","year":"2010","journal-title":"Discov Med."},{"issue":"7327","key":"10.1016\/j.ahj.2019.08.001_bb0090","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/nature09589","article-title":"Suppression of inflammation by a synthetic histone mimic","volume":"468","author":"Nicodeme","year":"2010","journal-title":"Nature."},{"issue":"6","key":"10.1016\/j.ahj.2019.08.001_bb0095","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018671","article-title":"Pharmacological inhibition of bromodomain-containing proteins in inflammation","volume":"6","author":"Schaefer","year":"2014","journal-title":"Cold Spring Harb Perspect Biol."},{"issue":"1","key":"10.1016\/j.ahj.2019.08.001_bb0100","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41467-017-01629-7","article-title":"Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells","volume":"8","author":"Das","year":"2017","journal-title":"Nat Commun."},{"issue":"11","key":"10.1016\/j.ahj.2019.08.001_bb0105","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/CIRCRESAHA.116.306819","article-title":"Epigenetic changes in diabetes and cardiovascular risk","volume":"118","author":"Keating","year":"2016","journal-title":"Circ Res."},{"issue":"1","key":"10.1016\/j.ahj.2019.08.001_bb0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molcel.2008.01.018","article-title":"The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription","volume":"30","author":"LeRoy","year":"2008","journal-title":"Mol Cell."},{"issue":"12","key":"10.1016\/j.ahj.2019.08.001_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083190","article-title":"RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist","volume":"8","author":"McLure","year":"2013","journal-title":"PLoS One."},{"issue":"49","key":"10.1016\/j.ahj.2019.08.001_bb0120","doi-asserted-by":"crossref","first-page":"19754","DOI":"10.1073\/pnas.1310658110","article-title":"RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain","volume":"110","author":"Picaud","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6345","key":"10.1016\/j.ahj.2019.08.001_bb0125","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1126\/science.aal2066","article-title":"Click chemistry enables preclinical evaluation of targeted epigenetic therapies","volume":"356","author":"Tyler","year":"2017","journal-title":"Science."},{"issue":"23","key":"10.1016\/j.ahj.2019.08.001_bb0130","first-page":"2580","article-title":"RVX-208","volume":"55","author":"Bailey","year":"2010","journal-title":"a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol."},{"key":"10.1016\/j.ahj.2019.08.001_bb0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2016.01.036","article-title":"RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I\/HDL and represses pathways that contribute to cardiovascular disease","volume":"247","author":"Gilham","year":"2016","journal-title":"Atherosclerosis."},{"issue":"1","key":"10.1016\/j.ahj.2019.08.001_bb0140","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2014.06.008","article-title":"A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice","volume":"236","author":"Jahagirdar","year":"2014","journal-title":"Atherosclerosis."},{"issue":"4","key":"10.1016\/j.ahj.2019.08.001_bb0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s12265-017-9755-z","article-title":"Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor apabetalone (RVX-208)","volume":"10","author":"Wasiak","year":"2017","journal-title":"J Cardiovasc Transl Res."},{"key":"10.1016\/j.ahj.2019.08.001_bb0150","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.dib.2016.07.047","article-title":"Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes","volume":"8","author":"Wasiak","year":"2016","journal-title":"Data Brief."},{"key":"10.1016\/j.ahj.2019.08.001_bb0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2018.11.002","article-title":"Apabetalone downregulates factors and pathways associated with vascular calcification","volume":"280","author":"Gilham","year":"2019","journal-title":"Atherosclerosis."},{"issue":"9","key":"10.1016\/j.ahj.2019.08.001_bb0160","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jacc.2010.11.015","article-title":"Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease","volume":"57","author":"Nicholls","year":"2011","journal-title":"a randomized controlled trial. J Am Coll Cardiol."},{"issue":"1","key":"10.1016\/j.ahj.2019.08.001_bb0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40256-015-0146-z","article-title":"Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial","volume":"16","author":"Nicholls","year":"2016","journal-title":"Am J Cardiovasc Drugs."},{"issue":"2","key":"10.1016\/j.ahj.2019.08.001_bb0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40256-017-0250-3","article-title":"Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease","volume":"18","author":"Nicholls","year":"2018","journal-title":"Am J Cardiovasc Drugs."},{"issue":"2","key":"10.1016\/j.ahj.2019.08.001_bb0175","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000488257","article-title":"Apabetalone mediated epigenetic modulation is associated with favorable kidney function and alkaline phosphatase profile in patients with chronic kidney disease","volume":"43","author":"Kulikowski","year":"2018","journal-title":"Kidney Blood Press Res."},{"issue":"3","key":"10.1016\/j.ahj.2019.08.001_bb0180","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ekir.2017.12.001","article-title":"Benefit of apabetalone on plasma proteins in renal disease","volume":"3","author":"Wasiak","year":"2018","journal-title":"Kidney Int Rep."},{"issue":"2","key":"10.1016\/j.ahj.2019.08.001_bb0185","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1573403X14666181031141226","article-title":"Tissue non-specific alkaline phosphatase and vascular calcification: a potential therapeutic target","volume":"15","author":"Azpiazu","year":"2019","journal-title":"Curr Cardiol Rev."},{"issue":"5","key":"10.1016\/j.ahj.2019.08.001_bb0190","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/ATVBAHA.112.300826","article-title":"Alkaline phosphatase, serum phosphate, and incident cardiovascular disease and total mortality in older men","volume":"33","author":"Wannamethee","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"11","key":"10.1016\/j.ahj.2019.08.001_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143355","article-title":"Association between serum alkaline phosphatase level and cerebral small vessel disease","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One."},{"issue":"1","key":"10.1016\/j.ahj.2019.08.001_bb0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11011-018-0322-3","article-title":"Alkaline phosphatase: a potential biomarker for stroke and implications for treatment","volume":"34","author":"Brichacek","year":"2019","journal-title":"Metab Brain Dis."},{"issue":"5","key":"10.1016\/j.ahj.2019.08.001_bb0205","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/eci.12752","article-title":"Alkaline phosphatase and prognosis in patients with coronary artery disease","volume":"47","author":"Ndrepepa","year":"2017","journal-title":"Eur J Clin Invest."},{"issue":"1","key":"10.1016\/j.ahj.2019.08.001_bb0210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000329722","article-title":"Alkaline phosphatase is increased in both brain and plasma in Alzheimer's disease","volume":"9","author":"Vardy","year":"2012","journal-title":"Neurodegener Dis."},{"issue":"42","key":"10.1016\/j.ahj.2019.08.001_bb0215","doi-asserted-by":"crossref","first-page":"32539","DOI":"10.1074\/jbc.M110.145003","article-title":"Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau","volume":"285","author":"Diaz-Hernandez","year":"2010","journal-title":"J Biol Chem."},{"issue":"4","key":"10.1016\/j.ahj.2019.08.001_bb0220","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc."},{"issue":"3","key":"10.1016\/j.ahj.2019.08.001_bb0225","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0168-8510(92)90164-7","article-title":"Health related quality of life measurement--Euro style","volume":"20","author":"Carr-Hill","year":"1992","journal-title":"Health Policy."},{"issue":"4","key":"10.1016\/j.ahj.2019.08.001_bb0230","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12265","article-title":"RVX 208: A novel BET protein inhibitor, role as an inducer of apo A-I\/HDL and beyond","volume":"35","author":"Ghosh","year":"2017","journal-title":"Cardiovasc Ther."},{"key":"10.1016\/j.ahj.2019.08.001_bb0235","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2018.11.002","article-title":"Apabetalone downregulates factors and pathways associated with vascular calcification","volume":"280","author":"Gilham","year":"2018","journal-title":"Atherosclerosis."},{"issue":"6","key":"10.1016\/j.ahj.2019.08.001_bb0240","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.metabol.2016.03.002","article-title":"Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial","volume":"65","author":"Siebel","year":"2016","journal-title":"Metabolism."},{"issue":"12","key":"10.1016\/j.ahj.2019.08.001_bb0245","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"issue":"14","key":"10.1016\/j.ahj.2019.08.001_bb0250","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ahj.2019.08.001_bb0255","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIR.0000000000000156","volume":"132","author":"Hicks","year":"2015","journal-title":"Circulation"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319301978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319301978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:56:50Z","timestamp":1762077410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319301978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":51,"alternative-id":["S0002870319301978"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.08.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}